Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy.
A case is reported in which a child with Duchenne muscular dystrophy received a dose of sugammadex to reverse a rocuronium-induced profound neuromuscular block. Sugammadex is the first selective relaxant binding agent and reverses rocuronium- and vecuronium-induced neuromuscular block. A fast and efficient recovery from profound neuromuscular block was achieved, and no adverse events or other safety concerns were observed.
Department of Anesthesiology and Pain Medicine, Martini General Hospital Groningen, Groningen, The Netherlands. HD.de.Boer@mzh.nl
Hans D
HD
de Boer
Jan
J
van Esmond
Leo H J D
LH
Booij
Jacques J
JJ
Driessen
D000732:Androstanols / Q000037:antagonists & inhibitors*; D000768:Anesthesia, General / Q000379:methods; D002648:Child; D006801:Humans; D006810:Humeral Fractures / Q000601:surgery; D008297:Male; D020388:Muscular Dystrophy, Duchenne / Q000150:complications*; D019148:Neuromuscular Blockade; D003473:Neuromuscular Nondepolarizing Agents / Q000037:antagonists & inhibitors*; D000077123:Rocuronium; D000077122:Sugammadex; D016896:Treatment Outcome; D047408:gamma-Cyclodextrins / Q000494:pharmacology*
D000732:Androstanols; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D000077123:Rocuronium